M. Vidal , R. Cárdenas-Perilla , A. Delgado , S. Morón , J.L. Londoño Blair , I. Vega , J.J. Correa Ochoa , J. Rojas
{"title":"抗去势转移性前列腺癌患者使用Radio-223的预后生物标志物","authors":"M. Vidal , R. Cárdenas-Perilla , A. Delgado , S. Morón , J.L. Londoño Blair , I. Vega , J.J. Correa Ochoa , J. Rojas","doi":"10.1016/j.remn.2023.06.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Establish basal biomarkers in patients with bone metastatic castration-resistant prostate cancer (mCRPC) treated with Ra-223 that predicted a better overall survival (OS), assess hematology toxicity and treatment response.</p></div><div><h3>Materials and methods</h3><p>Retrospective multicenter study in 151 patients with mCRPC between 2013 and 2020. OS was assessed according to basal hemoglobin (Hb), PSA, alkaline phosphatase (AP), WHO pain scale, Eastern Cooperative Oncology Group (ECOG), number of metastatic lesions on bone scan (BS), use of protective bone agents and received. Hematological toxicities were evaluated. Treatment response was based on changes in FA and pain.</p></div><div><h3>Results</h3><p>Median OS was 24<!--> <!-->months (95%<!--> <!-->CI: 16.5-31). OS in 70% of patients who received complete Ra-223 treatment (5-6 doses) was 34.9<!--> <!-->m vs. 5.8<!--> <!-->m in patients with incomplete treatment (1-4 doses). OS was longer in patients with lower PSA and AP, Hb<!--> <!-->><!--> <!-->13<!--> <!-->g/dL, lesser bone metastasis on GO and ECOG 0-1. 52/151 patients (34%) died during follow-up. Nearly 70% of patients experienced decrease in pain and 66% reduction on AP. Half of patients had mild hematological adverse effects and only 5% had severe.</p></div><div><h3>Conclusions</h3><p>mCRPC patients treated with Ra-223 who had Hb<!--> <!-->><!--> <!-->13<!--> <!-->g/mL, ECOG 0-1, low AP, PSA<!--> <!--><<!--> <!-->20<!--> <!-->ng/ml and lesser bone metastasis on BS shown a better OS with adequate safety profile.</p></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"42 5","pages":"Pages 310-317"},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarcadores pronósticos en el uso del radio-223 en pacientes con cáncer de próstata metastásico resistente a la castración\",\"authors\":\"M. Vidal , R. Cárdenas-Perilla , A. Delgado , S. Morón , J.L. Londoño Blair , I. Vega , J.J. Correa Ochoa , J. Rojas\",\"doi\":\"10.1016/j.remn.2023.06.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Establish basal biomarkers in patients with bone metastatic castration-resistant prostate cancer (mCRPC) treated with Ra-223 that predicted a better overall survival (OS), assess hematology toxicity and treatment response.</p></div><div><h3>Materials and methods</h3><p>Retrospective multicenter study in 151 patients with mCRPC between 2013 and 2020. OS was assessed according to basal hemoglobin (Hb), PSA, alkaline phosphatase (AP), WHO pain scale, Eastern Cooperative Oncology Group (ECOG), number of metastatic lesions on bone scan (BS), use of protective bone agents and received. Hematological toxicities were evaluated. Treatment response was based on changes in FA and pain.</p></div><div><h3>Results</h3><p>Median OS was 24<!--> <!-->months (95%<!--> <!-->CI: 16.5-31). OS in 70% of patients who received complete Ra-223 treatment (5-6 doses) was 34.9<!--> <!-->m vs. 5.8<!--> <!-->m in patients with incomplete treatment (1-4 doses). OS was longer in patients with lower PSA and AP, Hb<!--> <!-->><!--> <!-->13<!--> <!-->g/dL, lesser bone metastasis on GO and ECOG 0-1. 52/151 patients (34%) died during follow-up. Nearly 70% of patients experienced decrease in pain and 66% reduction on AP. Half of patients had mild hematological adverse effects and only 5% had severe.</p></div><div><h3>Conclusions</h3><p>mCRPC patients treated with Ra-223 who had Hb<!--> <!-->><!--> <!-->13<!--> <!-->g/mL, ECOG 0-1, low AP, PSA<!--> <!--><<!--> <!-->20<!--> <!-->ng/ml and lesser bone metastasis on BS shown a better OS with adequate safety profile.</p></div>\",\"PeriodicalId\":48986,\"journal\":{\"name\":\"Revista Espanola De Medicina Nuclear E Imagen Molecular\",\"volume\":\"42 5\",\"pages\":\"Pages 310-317\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola De Medicina Nuclear E Imagen Molecular\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2253654X23000707\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Medicina Nuclear E Imagen Molecular","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253654X23000707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Biomarcadores pronósticos en el uso del radio-223 en pacientes con cáncer de próstata metastásico resistente a la castración
Objectives
Establish basal biomarkers in patients with bone metastatic castration-resistant prostate cancer (mCRPC) treated with Ra-223 that predicted a better overall survival (OS), assess hematology toxicity and treatment response.
Materials and methods
Retrospective multicenter study in 151 patients with mCRPC between 2013 and 2020. OS was assessed according to basal hemoglobin (Hb), PSA, alkaline phosphatase (AP), WHO pain scale, Eastern Cooperative Oncology Group (ECOG), number of metastatic lesions on bone scan (BS), use of protective bone agents and received. Hematological toxicities were evaluated. Treatment response was based on changes in FA and pain.
Results
Median OS was 24 months (95% CI: 16.5-31). OS in 70% of patients who received complete Ra-223 treatment (5-6 doses) was 34.9 m vs. 5.8 m in patients with incomplete treatment (1-4 doses). OS was longer in patients with lower PSA and AP, Hb > 13 g/dL, lesser bone metastasis on GO and ECOG 0-1. 52/151 patients (34%) died during follow-up. Nearly 70% of patients experienced decrease in pain and 66% reduction on AP. Half of patients had mild hematological adverse effects and only 5% had severe.
Conclusions
mCRPC patients treated with Ra-223 who had Hb > 13 g/mL, ECOG 0-1, low AP, PSA < 20 ng/ml and lesser bone metastasis on BS shown a better OS with adequate safety profile.
期刊介绍：
The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members.
The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
